These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28831727)

  • 1. Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms.
    Hermans A; Abend AM; Kesisoglou F; Flanagan T; Cohen MJ; Diaz DA; Mao Y; Zhang L; Webster GK; Lin Y; Hahn DA; Coutant CA; Grady H
    AAPS J; 2017 Nov; 19(6):1537-1549. PubMed ID: 28831727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.
    Yang R; Lin Y; Chen K; Huang J; Yang S; Yao A; Yang X; Lei D; Xiao J; Yang G; Pei Q
    AAPS J; 2024 Jul; 26(4):82. PubMed ID: 38997548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing.
    Zaborenko N; Shi Z; Corredor CC; Smith-Goettler BM; Zhang L; Hermans A; Neu CM; Alam MA; Cohen MJ; Lu X; Xiong L; Zacour BM
    AAPS J; 2019 Feb; 21(3):32. PubMed ID: 30790200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets.
    Paraiso RLM; Rose RH; Fotaki N; McAllister M; Dressman JB
    Eur J Pharm Sci; 2020 Dec; 155():105534. PubMed ID: 32871212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report.
    Suarez-Sharp S; Cohen M; Kesisoglou F; Abend A; Marroum P; Delvadia P; Kotzagiorgis E; Li M; Nordmark A; Bandi N; Sjögren E; Babiskin A; Heimbach T; Kijima S; Mandula H; Raines K; Seo P; Zhang X
    AAPS J; 2018 Aug; 20(6):93. PubMed ID: 30151612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
    Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
    J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
    Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
    AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring clinically relevant dissolution specifications for oral solid dosage forms of weak acid drugs using an in silico modeling and simulation approach.
    Kambayashi A; Yomota C
    Eur J Pharm Sci; 2021 Apr; 159():105728. PubMed ID: 33484814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.